Scarica l'app Stockscreener
366.20
0.10%
-0.38
Dopo l'orario di chiusura:
366.40
0.20
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$366.58
Aprire:
$366.66
Volume 24 ore:
2.31M
Relative Volume:
0.80
Capitalizzazione di mercato:
$197.38B
Reddito:
$36.71B
Utile/perdita netta:
$7.71B
Rapporto P/E:
25.74
EPS:
14.2284
Flusso di cassa netto:
$9.96B
1 W Prestazione:
-0.44%
1M Prestazione:
+12.49%
6M Prestazione:
+28.50%
1 anno Prestazione:
+24.11%
Intervallo 1D:
$365.06
$370.88
Intervallo di 1 settimana:
$361.00
$385.12
Portata 52W:
$261.43
$385.12
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
366.20 | 197.59B | 36.71B | 7.71B | 9.96B | 14.23 |
|
LLY
Lilly Eli Co
|
1,038.27 | 908.63B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
244.55 | 580.30B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
227.50 | 390.40B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.52 | 317.44B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
161.18 | 305.42B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update - Yahoo Finance
AMGN: Advancing late-stage trials and expanding TSLP-targeted therapies, with major data readouts ahead - TradingView
Traders Buy Large Volume of Amgen Call Options (NASDAQ:AMGN) - MarketBeat
Amgen wins EC approval for Uplizna in gMG - The Pharma Letter
Amgen wins EC approval for Uplinza in gMG - The Pharma Letter
Varma Mutual Pension Insurance Co Buys 7,300 Shares of Amgen Inc. $AMGN - MarketBeat
EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS - PR Newswire
Leuthold Group LLC Purchases New Stake in Amgen Inc. $AMGN - MarketBeat
Stratos Wealth Partners LTD. Has $8.83 Million Stake in Amgen Inc. $AMGN - MarketBeat
Cibc World Market Inc. Grows Stake in Amgen Inc. $AMGN - MarketBeat
ABC Arbitrage SA Cuts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings - Nasdaq
Amgen (NASDAQ:AMGN) Price Target Raised to $295.00 - MarketBeat
Rhumbline Advisers Sells 6,685 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 - simplywall.st
Prospera Financial Services Inc Sells 6,723 Shares of Amgen Inc. $AMGN - MarketBeat
Caprock Group LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Wealthfront Advisers LLC Grows Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Reduced by Allegheny Financial Group - MarketBeat
How Amgen Inc. (AMGN) Affects Rotational Strategy Timing - Stock Traders Daily
AstraZeneca Unit Settles Soliris Feud With Samsung, Amgen - Law360
Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating - marketscreener.com
Daiwa Securities Group Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend - 富途牛牛
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Two Days Left Until Amgen Inc. (NASDAQ:AMGN) Trades Ex-Dividend - simplywall.st
Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating - marketscreener.com
The 5 Most Interesting Analyst Questions From Amgen's Q4 Earnings Call - Finviz
The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call - The Globe and Mail
Alps Advisors Inc. Has $5.29 Million Stake in Amgen Inc. $AMGN - MarketBeat
Wesbanco Bank Inc. Increases Stake in Amgen Inc. $AMGN - MarketBeat
First National Trust Co Trims Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Amgen stands by vasculitis drug Tavneos after FDA wants it pulled - ANCA Vasculitis News
When Advocacy Meets Science in the Care of People Living with gMG - Amgen
Amgen, Merck share losses contribute to Dow's 200-point drop - MSN
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Candriam S.C.A. Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
ProShare Advisors LLC Sells 158,994 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock jumps to a 52-week high; here’s what to watch before Monday’s open - TechStock²
Kinsale Capital Group Inc. Has $9.65 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Acquires 2,967 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock price hits 52-week high after Friday rally — what to watch into Monday - TechStock²
The Truth About Amgen Inc.: Is This Quiet Biotech Giant Your Next Power Move? - AD HOC NEWS
Amgen’s Stock Is Already Up 14% in 2026: Why Analysts Expect $440 - TIKR.com
Twin Capital Management Inc. Sells 5,541 Shares of Amgen Inc. $AMGN - MarketBeat
Renaissance Group LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
SBI Securities Co. Ltd. Has $977,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - Sahm
Amgen (NASDAQ:AMGN) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.56%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):